Where our materials reference NAD+, cellular repair, or healthy aging, those statements describe findings from published preclinical and early clinical research — not proven outcomes for any individual patient. NAD+ is a coenzyme required for DNA-repair enzymes (PARPs) and sirtuins, and its tissue levels decline with age. Human trials of NAD+ precursors have consistently shown that oral supplementation raises blood NAD+ levels and is well tolerated, but clinical benefit endpoints such as longevity, reversal of aging, or DNA-repair capacity in humans have not been established.
We do not claim that NAD+ therapy repairs DNA, extends lifespan, or replaces surgical or medical treatment. Any protocol is provided as part of clinician-supervised care after individual evaluation.
Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141.
Review of how NAD+ supports sirtuin and PARP-dependent DNA repair, and how NAD+ availability declines with age.
View sourceRajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547.
Summarizes animal evidence for NAD+ precursors and notes that human outcome data remain limited.
View sourceMartens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.
Randomized placebo-controlled trial showing NAD+ elevation and good tolerability, without proven anti-aging outcomes.
View sourceElhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome. Cell Rep. 2019;28(7):1717-1728.
Demonstrates measurable NAD+ metabolome changes in older adults, with no significant change in muscle function endpoints.
View source
These statements have not been evaluated by the FDA. NAD+ and related products are not intended to diagnose, treat, cure, or prevent any disease.